medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 1

<< Back Next >>

Acta Med 2021; 19 (1)

Epidemiological characteristics of pharmacodermia in a private hospital

Moreno OLG, López ZBE, Díaz GEJ, Rodríguez WFL, Solís SA

Language: Spanish
References: 16
Page: 76-80
PDF size: 156.06 Kb.


ABSTRACT

Introduction: The pharmacodermias are a health problem with increasing annual incidence, especially due to the growing craze for self-medication and polypharmacy. Drug-associated skin reactions present degrees of severity and despite representing a latent health risk, there is little information on the Mexican population, which makes necessary their epidemiological characterization. Material and methods: Observational, descriptive, retrospective, and cross-sectional study. Hospitalized patients at Hospital Ángeles Pedregal, older than 15 years, with clinical suspicion of adverse effects to systemic drugs with mucocutaneous manifestations, were included in a period from January 2016 to December 2018. Results: 35,592 individuals were studied, a cumulative incidence of 5.28 cases per 1,000 hospitalized patients was identified, most of them female sex (63%) with an average age of 49.1 (± 17) years. The most frequent symptom was pruritus, associated to maculopapular rash, angioedema, urticaria and anaphylactic shock. With antibiotics identified as the main cause (40.4%). Conclusions: The results obtained agree with what has been stated internationally pointing to antibiotics, as part of the drugs most frequently associated with the presence of adverse events. The incidence in the presentation of these manifestations reached up to 0.49% of the hospitalized population and 1 in 62 patients with an adverse event will suffer from a life-threatening drug reaction.


REFERENCES

  1. Boletín CONAMED-OPS. 2015; 3-5.

  2. Aguilar Escobar J, Calvi Fernández R. Toxicodermias. Erupciones cutáneas por fármacos. Gac Med Bol. 2008; 31 (1): 68-68.

  3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279 (15): 1200-1205.

  4. Reynoso DC, Villagrán PM, Rodríguez MN, Rodríguez BS, Acosta RCA, Alcántar LE et al. Abordaje terapéutico del síndrome de necrólisis epidérmica tóxica (síndrome de Brocq-Lyell). Dermatol Rev Mex. 2009; 53 (6): 288-294.

  5. Roberts DL, Marks R. Skin reactions to carbamazepine. Arch Dermatol. 1981; 117 (5): 273-275.

  6. Sáustegui I, Campos KI, Domínguez J, Méndez S. Reacciones cutáneas adversas a medicamentos. Rev Med Inst Mex Seguro Soc. 2018; 56 (1): 64-70.

  7. Hernández SA, Vega ME, Hojyo TMT. Epidemiología de las reacciones cutáneas adversas a fármacos, en el Servicio de Dermatología del Hospital General Dr. Manuel Gea González. Dermatol Rev Mex. 2011; 55 (6): 327-333.

  8. NORMA Oficial Mexicana NOM-220-SSA1-2016, Instalación y operación de la farmacovigilancia. Diario Oficial de la Federación. Fecha de publicación: 15 de enero de 2018.

  9. Kim GY, Anderson KR, Davis DMR, Hand JL, Tollefson MM. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature. J Am Acad Dermatol. 2020; 83 (5): 1323-1330. doi: 10.1016/j.jaad.2020.03.081.

  10. Marzano AV, Borghi A, Cugno M. Adverse drug reactions and organ damage: the skin. Eur J Intern Med. 2016; 28: 17-24.

  11. Yerenas García C. Reacciones adversas a fármacos en la Unidad Médica de Alta Especialidad CMNO IMMS. Tesis 2008.

  12. Chávez-Lemus FA, Reynoso-von Drateln C, Rodríguez-Martínez N. Prevalencia de las farmacodermias en pacientes hospitalizados en el Servicio de Dermatología de la UMAE del Centro Médico Nacional de Occidente. Periodo 2004-2012. Dermatol Rev Mex. 2014; 58 (4): 339-345.

  13. Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019; 17: 100188.

  14. D'Souza P, Gupta S, Gupta LK, Agarwal N, Akhilesh S. Cutaneous adverse drug reactions. In: Majid I. IADVL recent advances in dermatology. New Delhi, India: Jaypee Brothers Medical Publishers; 2016. pp. 113-129.

  15. Rodríguez BL, García VJL, Giral BC, Hernández SD, Jasso GL. Farmacovigilancia III. La experiencia internacional. Rev Med Inst Mex Seguro Soc. 2005; 43 (2): 131-140.

  16. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011; 7 (6): 349-359.




2020     |     www.medigraphic.com